Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial targets hardening skin in rare autoimmune disease

NCT ID NCT05198557

Summary

This study is testing whether an investigational drug called MT-0551 can reduce skin thickening in people with systemic sclerosis, a rare autoimmune disease that causes hardening of the skin and internal organs. The trial will compare MT-0551 against a placebo in 80 patients over 26 weeks, measuring changes in skin thickness and lung function. The goal is to see if the drug can better control disease progression and improve patients' symptoms.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • St. Marianna University Hospital

    Kawasaki-shi, Kanagawa, 216-8511, Japan

  • The University of Tokyo Hospital

    Bunkyo-ku, Tokyo, 113-8655, Japan

  • University of Fukui Hospital

    Yoshida-gun, Fukui, 910-1193, Japan

Conditions

Explore the condition pages connected to this study.